307 related articles for article (PubMed ID: 32303613)
1. Immune involvement of the contralateral hemisphere in a glioblastoma mouse model.
Crommentuijn MHW; Schetters STT; Dusoswa SA; Kruijssen LJW; Garcia-Vallejo JJ; van Kooyk Y
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303613
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
[TBL] [Abstract][Full Text] [Related]
3. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G
Front Immunol; 2021; 12():637146. PubMed ID: 34025646
[TBL] [Abstract][Full Text] [Related]
4. 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.
Woroniecka KI; Rhodin KE; Dechant C; Cui X; Chongsathidkiet P; Wilkinson D; Waibl-Polania J; Sanchez-Perez L; Fecci PE
Clin Cancer Res; 2020 Mar; 26(6):1349-1358. PubMed ID: 31871298
[TBL] [Abstract][Full Text] [Related]
5. T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.
Woroniecka K; Chongsathidkiet P; Rhodin K; Kemeny H; Dechant C; Farber SH; Elsamadicy AA; Cui X; Koyama S; Jackson C; Hansen LJ; Johanns TM; Sanchez-Perez L; Chandramohan V; Yu YA; Bigner DD; Giles A; Healy P; Dranoff G; Weinhold KJ; Dunn GP; Fecci PE
Clin Cancer Res; 2018 Sep; 24(17):4175-4186. PubMed ID: 29437767
[No Abstract] [Full Text] [Related]
6. Immune Checkpoint Inhibitor-induced Reinvigoration of Tumor-infiltrating CD8
Park J; Kwon M; Kim KH; Kim TS; Hong SH; Kim CG; Kang SG; Moon JH; Kim EH; Park SH; Chang JH; Shin EC
Clin Cancer Res; 2019 Apr; 25(8):2549-2559. PubMed ID: 30659023
[TBL] [Abstract][Full Text] [Related]
7. Preclinical ImmunoPET Imaging of Glioblastoma-Infiltrating Myeloid Cells Using Zirconium-89 Labeled Anti-CD11b Antibody.
Nigam S; McCarl L; Kumar R; Edinger RS; Kurland BF; Anderson CJ; Panigrahy A; Kohanbash G; Edwards WB
Mol Imaging Biol; 2020 Jun; 22(3):685-694. PubMed ID: 31529407
[TBL] [Abstract][Full Text] [Related]
8. Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes.
Mohme M; Schliffke S; Maire CL; Rünger A; Glau L; Mende KC; Matschke J; Gehbauer C; Akyüz N; Zapf S; Holz M; Schaper M; Martens T; Schmidt NO; Peine S; Westphal M; Binder M; Tolosa E; Lamszus K
Clin Cancer Res; 2018 Sep; 24(17):4187-4200. PubMed ID: 29444930
[No Abstract] [Full Text] [Related]
9. Immune-Checkpoint Blockade Opposes CD8
Pfannenstiel LW; Diaz-Montero CM; Tian YF; Scharpf J; Ko JS; Gastman BR
Cancer Immunol Res; 2019 Mar; 7(3):510-525. PubMed ID: 30728151
[TBL] [Abstract][Full Text] [Related]
10. Aging- and Tumor-Mediated Increase in CD8
Huff WX; Bam M; Shireman JM; Kwon JH; Song L; Newman S; Cohen-Gadol AA; Shapiro S; Jones T; Fulton K; Liu S; Tanaka H; Liu Y; Wan J; Dey M
Immunohorizons; 2021 Jun; 5(6):395-409. PubMed ID: 34103370
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of HLA-II related to LAG-3
Guo W; Peng D; Liao Y; Lou L; Guo M; Li C; Yu W; Tian X; Wang G; Lv P; Zuo J; Shen H; Li Y
Cancer Sci; 2024 May; 115(5):1388-1404. PubMed ID: 38480275
[TBL] [Abstract][Full Text] [Related]
12. Glioblastoma-Infiltrating CD8+ T Cells Are Predominantly a Clonally Expanded GZMK+ Effector Population.
Wang AZ; Mashimo BL; Schaettler MO; Sherpa ND; Leavitt LA; Livingstone AJ; Khan SM; Li M; Anzaldua-Campos MI; Bradley JD; Leuthardt EC; Kim AH; Dowling JL; Chicoine MR; Jones PS; Choi BD; Cahill DP; Carter BS; Petti AA; Johanns TM; Dunn GP
Cancer Discov; 2024 Jun; 14(6):1106-1131. PubMed ID: 38416133
[TBL] [Abstract][Full Text] [Related]
13. The Prognostic Landscape of Tumor-Infiltrating Immune Cells and Immune Checkpoints in Glioblastoma.
Wu S; Yang W; Zhang H; Ren Y; Fang Z; Yuan C; Yao Z
Technol Cancer Res Treat; 2019 Jan; 18():1533033819869949. PubMed ID: 31451090
[TBL] [Abstract][Full Text] [Related]
14. Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment.
Wu A; Maxwell R; Xia Y; Cardarelli P; Oyasu M; Belcaid Z; Kim E; Hung A; Luksik AS; Garzon-Muvdi T; Jackson CM; Mathios D; Theodros D; Cogswell J; Brem H; Pardoll DM; Lim M
J Neurooncol; 2019 Jun; 143(2):241-249. PubMed ID: 31025274
[TBL] [Abstract][Full Text] [Related]
15. Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.
Lamano JB; Lamano JB; Li YD; DiDomenico JD; Choy W; Veliceasa D; Oyon DE; Fakurnejad S; Ampie L; Kesavabhotla K; Kaur R; Kaur G; Biyashev D; Unruh DJ; Horbinski CM; James CD; Parsa AT; Bloch O
Clin Cancer Res; 2019 Jun; 25(12):3643-3657. PubMed ID: 30824583
[TBL] [Abstract][Full Text] [Related]
16. Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy.
Panagioti E; Kurokawa C; Viker K; Ammayappan A; Anderson SK; Sotiriou S; Chatzopoulos K; Ayasoufi K; Johnson AJ; Iankov ID; Galanis E
J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34196308
[TBL] [Abstract][Full Text] [Related]
17. Tumor cell and immune cell profiles in primary human glioblastoma: Impact on patient outcome.
González-Tablas Pimenta M; Otero Á; Arandia Guzman DA; Pascual-Argente D; Ruíz Martín L; Sousa-Casasnovas P; García-Martin A; Roa Montes de Oca JC; Villaseñor-Ledezma J; Torres Carretero L; Almeida M; Ortiz J; Nieto A; Orfao A; Tabernero MD
Brain Pathol; 2021 Mar; 31(2):365-380. PubMed ID: 33314398
[TBL] [Abstract][Full Text] [Related]
18. Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine.
Liu CJ; Schaettler M; Blaha DT; Bowman-Kirigin JA; Kobayashi DK; Livingstone AJ; Bender D; Miller CA; Kranz DM; Johanns TM; Dunn GP
Neuro Oncol; 2020 Sep; 22(9):1276-1288. PubMed ID: 32133512
[TBL] [Abstract][Full Text] [Related]
19. Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.
Karachi A; Yang C; Dastmalchi F; Sayour EJ; Huang J; Azari H; Long Y; Flores C; Mitchell DA; Rahman M
Neuro Oncol; 2019 Jun; 21(6):730-741. PubMed ID: 30668768
[TBL] [Abstract][Full Text] [Related]
20. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]